Patents by Inventor C. David Pauza

C. David Pauza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pertussis toxin induced lymphocytosis
    Patent number: 6027731
    Abstract: A therapeutic remodeling of immune system for HIV evaluation and AIDS treatment. Specifically, the present invention involves eliciting lymphocytosis in order to reveal the sequestered HIV or SIV in the lymph tissues enabling HIV infection analysis, viral quantification and treatment. The lymphocytosis itself causes an alleviation of the AIDS symptoms and a reduction in the viral load. The present invention could also be used in conjunction with a large variety of adjunct therapies.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: February 22, 2000
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: C. David Pauza
  • Pertussis toxin induced lymphocytosis
    Patent number: 5888726
    Abstract: The present invention involves HIV evaluation and AIDS treatment by eliciting lymphocytosis with pertussis toxin in order to reveal the sequestered HIV or SIV in the lymph tissues enabling HIV infection analysis, viral quantification and treatment. The lymphocytosis itself causes an alleviation of the AIDS symptoms and a reduction in the viral load. The present invention could also be used in conjunction with a large variety of adjunct therapies.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: March 30, 1999
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: C. David Pauza, Jr.
  • Use of .DELTA.5 androstenes in the treatment of HIV wasting syndrome
    Patent number: 5885977
    Abstract: HIV-related weight loss, HIV-related cachexia and HIV-related wasting syndrome can be treated by administering therapeutic amounts of the steroid .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors thereof, such as .DELTA.5-androstene-3.beta.-acetoxy-7,17 dione, which are readily metabolized in vivo to .DELTA.5 androstene-3.beta.-ol-7,17 dione. Such treatment can be prophylactic, modulatory, ameliorative or curative in nature.
    Type: Grant
    Filed: January 15, 1997
    Date of Patent: March 23, 1999
    Assignee: Humanetics Corporation
    Inventors: C. David Pauza, Henry A. Lardy